| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1044391773 |
| P356 | DOI | 10.1007/S11926-009-0054-9 |
| P932 | PMC publication ID | 3033497 |
| P698 | PubMed publication ID | 19772834 |
| P5875 | ResearchGate publication ID | 26830161 |
| P50 | author | Eric M Ruderman | Q56971136 |
| P2093 | author name string | Harris Perlman | |
| Melissa Mavers | |||
| P2860 | cites work | Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity | Q28293265 |
| Structure and function of Syk protein-tyrosine kinase | Q28624023 | ||
| Effects of paclitaxel on cultured synovial cells from patients with rheumatoid arthritis | Q31000977 | ||
| Role of PI3Kdelta and PI3Kgamma in inflammatory arthritis and tissue localization of neutrophils | Q34273300 | ||
| Regulation of apoptosis and cell cycle activity in rheumatoid arthritis | Q34567325 | ||
| CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders | Q34980351 | ||
| Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis | Q35025556 | ||
| The JAK-STAT signaling pathway: input and output integration | Q36740971 | ||
| NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint | Q36803920 | ||
| Role of mitogen-activated protein kinase kinase kinases in signal integration | Q36819381 | ||
| The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis | Q36934993 | ||
| Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis | Q37007690 | ||
| Macrophage activation by endogenous danger signals | Q37045743 | ||
| Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis | Q37139284 | ||
| Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550) | Q37139740 | ||
| Primer: Toll-like receptor signaling pathways--what do rheumatologists need to know? | Q37150726 | ||
| The CDK domain of p21 is a suppressor of IL-1beta-mediated inflammation in activated macrophages | Q37324160 | ||
| Cell death in rheumatoid arthritis | Q37387083 | ||
| Regulation of the immune response by stress-activated protein kinases | Q37416266 | ||
| Tyrosine kinases as targets for the treatment of rheumatoid arthritis | Q37506087 | ||
| Characterization of (2R, 3S)-2-([[4-(2-butynyloxy)phenyl]sulfonyl]amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-alpha converting enzyme | Q40494753 | ||
| Local treatment with the selective IkappaB kinase beta inhibitor NEMO-binding domain peptide ameliorates synovial inflammation | Q41994314 | ||
| Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases | Q44571180 | ||
| A highly selective inhibitor of I kappa B kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice | Q44586798 | ||
| Intra-articular treatment of arthritis with microsphere formulations of paclitaxel: biocompatibility and efficacy determinations in rabbits | Q45022246 | ||
| Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation | Q45879224 | ||
| The Bcl-2 family antagonist ABT-737 significantly inhibits multiple animal models of autoimmunity. | Q45983884 | ||
| Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. | Q46030933 | ||
| Effect of CP-690,550, an orally active janus kinase inhibitor, on renal function in healthy adult volunteers | Q46076169 | ||
| Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis | Q46140186 | ||
| Inhibition of p38: has the fat lady sung? | Q46140191 | ||
| Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial | Q46271720 | ||
| Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. | Q46674143 | ||
| Central role of the MEK/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: potential proinflammatory mechanisms | Q46973396 | ||
| A novel, highly selective, tight binding IkappaB kinase-2 (IKK-2) inhibitor: a tool to correlate IKK-2 activity to the fate and functions of the components of the nuclear factor-kappaB pathway in arthritis-relevant cells and animal models. | Q54770955 | ||
| Rheumatoid arthritis | Q74541001 | ||
| The Jak-STAT pathway in rheumatoid arthritis | Q81162711 | ||
| Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1 | Q81544547 | ||
| Spleen tyrosine kinase: a novel target for therapeutic intervention of rheumatoid arthritis | Q94699138 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 378-385 | |
| P577 | publication date | 2009-10-01 | |
| P1433 | published in | Current Rheumatology Reports | Q23930052 |
| P1476 | title | Intracellular signal pathways: potential for therapies | |
| P478 | volume | 11 |
| Q53791793 | A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate. |
| Q35658843 | Cyclin-dependent kinase inhibitor p21, via its C-terminal domain, is essential for resolution of murine inflammatory arthritis |
| Q34079139 | Dynamical and structural analysis of a T cell survival network identifies novel candidate therapeutic targets for large granular lymphocyte leukemia |
| Q24658506 | Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study |
| Q61807322 | Inhibition of pSTAT1 by tofacitinib accounts for the early improvement of experimental chronic synovitis |
| Q38761142 | JAK inhibition in inflammatory bowel disease |
| Q37148745 | JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines |
| Q38751230 | JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. |
| Q35592159 | MassSQUIRM: An assay for quantitative measurement of lysine demethylase activity |
| Q54356823 | Participation of PI3K, MAPK ERK1/2, and p38 in the realization of growth potential of mesenchymal precursor cells under in vitro conditions. |
| Q26744032 | Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same? |
| Q30244019 | Rheumatoid arthritis. |
| Q54391644 | Role of cAMP and IKK-2-dependent signaling in the realization of growth potential of mesenchymal progenitor cells. |
| Q26825791 | Some perspectives on network modeling in therapeutic target prediction |
| Q35605477 | The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis |
| Q44581309 | The expanding therapeutic armamentarium for inflammatory bowel disease: how to choose the right drug(s) for our patients? |
| Q37702568 | The immunomodulatory effects of TNF-α inhibitors on human Th17 cells via RORγt histone acetylation |
| Q38366902 | Tyrosine kinases in rheumatoid arthritis |
| Q35822379 | Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm Meeting |
| Q49210038 | Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2017 MauiDerm Meeting |
Search more.